Healthcare / BiotechnologyNasdaqCM
$2.97
-0.08 (-2.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-21.6M · quality 55.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$133M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-278.5%
↓Gross Margin
N/A
•Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-91.0%
FCF CAGR
—
FCF margin
-329575.0%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8000.0 · net income $-32.1M · FCF $-26.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8000.00 | $8000.00 | $8000.00 | $170000.00 | $11.1M |
| Net Income | $-32.1M | $-32.1M | $-29.9M | $-28.3M | $-5.2M |
| EBITDA | $-32.6M | $-32.6M | $-30.8M | $-26.5M | $-1.7M |
| EPS | — | — | -0.95 | -1.16 | -0.22 |
| Operating Margin | -415175.0% | -415175.0% | -396200.0% | -14214.7% | -27.2% |
| Net Margin | -401812.5% | -401812.5% | -373362.5% | -16645.3% | -47.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.07 | 0.13 | -0.74 |
| Current Ratio | 3.68 | 3.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.4M | $-26.4M | $-21.6M | $-21.3M | $-3.6M |
| Returns | |||||
| ROE | -278.5% | -278.5% | -113.7% | -145.3% | 14.6% |
| Valuation | |||||
| P/B | 9.81 | 9.81 | 3.04 | 17.44 | — |
| Growth & Yield | |||||
| Revenue Growth | 0.0% | 0.0% | -95.3% | -98.5% | — |
| EPS Growth | — | — | 18.1% | -425.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.95 → n/d
Residual
+22.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.